Skip to main content

CMS Opioids Roadmap

June 11, 2018

CMS Opioids Roadmap

Although some progress has been made in efforts to combat the opioid epidemic, the latest data from the Centers for Disease Control and Prevention indicate the crisis is not slowing down. However, it is important for our beneficiaries across the country to know that the Centers for Medicare & Medicaid Services (CMS) is exploring all of our options to address this national crisis.

As evidence of our commitment to the health and well-being of patients, CMS is publishing a roadmap outlining our efforts to address this issue of national concern. In this roadmap, we detail our three-pronged approach to combating the opioid epidemic, focusing in on prevention of new cases of opioid use disorder (OUD), the treatment of patients who have already become dependent on or addicted to opioids, and the utilization of data from across the country to target prevention and treatment activities.

Current estimates show that over two million[i] people suffer from opioid use disorder, with a prevalence in Medicare of 6 out of every 1,000 beneficiaries.[ii] In order to decrease that number, it is crucial that Medicare beneficiaries and providers are aware that there are options available for both prevention of developing new cases of OUD and the treatment of existing cases. CMS is working to ensure that beneficiaries are not inadvertently put at risk of misuse by closely monitoring prescription opioid trends, strengthening controls at the time of opioid prescriptions, and encouraging healthcare providers to promote a range of safe and effective pain treatments, including alternatives to opioids. We are also working on communications with beneficiaries to explain the risks of prescription opioids and how to safely dispose of them, so they are not misused by others. These are just some of the ways we are looking to protect and care for people with Medicare.

CMS also recognizes that the opioid epidemic has affected people covered by Medicaid across the country in different ways – an estimated 8.7 out of 1,000 Medicaid beneficiaries are impacted by OUD. We believe one crucial effort to help on the treatment front is encouraging states to tailor programs to their populations by taking advantage of flexibilities that are available through Medicaid Section 1115 substance use disorder (SUD) demonstrations that improve OUD treatment.  CMS has worked with seven new states since October 2017 to approve waivers to tackle the opioid epidemic in their state. With each state having a unique population, we recognize the challenges that states face in creating programs to help, and we are committed to providing the support necessary to help states achieve positive results for their populations.

Beyond Medicare and Medicaid, CMS is also looking across our other programs to use all the tools at our disposal to address the opioid crisis. We are working to ensure that the private plans offering coverage on the Health Insurance Exchanges also provide options for treating OUD, and we are examining our quality standards across our programs to encourage providers to follow best practice guidelines related to opioid misuse diagnosis and treatment. Further, while we have initiatives specific to Medicare and Medicaid, we are also reviewing all of our programs to find solutions that are working at the local level with states, providers, and payers so that we can disseminate successful ideas as quickly as possible to help our partners know that they do not have to solve this alone.

CMS believes we can make progress in addressing the many aspects of the opioid epidemic in partnership with states and other stakeholder organizations. Every day this crisis claims the lives of loved ones and, in many areas in our country, we have yet to turn the tide. This roadmap is only a start, and as we begin to implement many of our plans and programs, it will continue to evolve. But the roadmap is also a demonstration of CMS’ commitment to explore and offer viable options to address the crisis, to share the information we collect with other agencies and organizations, and to protect our beneficiaries and communities affected by the crisis.

[i] https://www.hhs.gov/opioids/about-the-epidemic/index.html

[ii] https://www.cms.gov/Outreach-and-Education/Outreach/Partnerships/Downloads/CMS-Opioid-Misuse-Strategy-2016.pdf



from The CMS Blog https://ift.tt/2HCwUk8
via IFTTT

Become a patron of The Carlisle Wellness Network. Show everyone that you think this service is worth at least a buck. Go to; https://www.patreon.com/carlislewellness and pledge one dollar per month and help improve the resources it takes to gather the articles you see here as well as create fresh content including interviews an podcasts. We only need one dollar per month from all of our patrons to give The Carlisle Wellness Network a bright furture in the health and wellness social media ecosystem.

Comments

Popular posts from this blog

PET Imaging Agent Can ID Good Candidates for Depression Drug

A new brain imaging agent could reveal — before any treatment has been prescribed — whether a patient with major depressive disorder (MDD) is likely to respond to a particular antidepressant, according to a new study published in The Journal of Nuclear Medicine. No such marker is currently available in clinical psychiatry.Escitalopram (Lexapro), a selective serotonin reuptake inhibitor (SSRI), can be an effective MDD treatment for some patients, but not all. During  positron emission tomography (PET) test, the tracer 11C-DASB targets the serotonin transporter protein (5-HTT) in the amygdala of the brain, a region associated with emotional processing.In the study, patients shown to have less 5-HTT protein were those who later experienced relief from escitalopram.“MDD is a heterogeneous disorder, which makes it extremely difficult to treat effectively,” said researcher Mala R. Ananth, a graduate student at Stony Brook University in Stony Brook, N.Y.“Optimizing treatment is challenging a…

Reducing Alzheimer’s Stigma Could Enhance Research

A new study suggests ongoing research on Alzheimer’s disease may be challenged by the stigma associated with the disease. This concern comes from the results of a national survey which discovered people may be afraid to admit they have early stage Alzheimer’s because of fear of discrimination — especially potential limitations on their health insurance.Researchers say these fears can hopefully be overcome by the development of new policies to protect individuals. Nondisclosure of early symptoms that may or may not be Alzheimer’s hinders a individuals ability to obtain timely care. Additionally, a person may miss the opportunity to participate in clinical studies that discover potential therapies.The finding are the results of a national survey about what beliefs, attitudes and expectations are most often associated with Alzheimer’s disease. The survey results appear in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association.“We found that concerns about discrimination a…

Hair Pulling, Nail Biting, Skin Peeling and Biting

All my life I’ve bitten my nails. It’s caused me a lot of trouble, especially with my bipolar mother who has always thought screaming and shouting at me (and often a smack when I was younger) would make me stop.At around 7 I also started biting and peeling the skin on my fingers which has caused a lot of social and health issues for me from being to ashamed to join in with prayers at school, to getting my fingers getting a fungal infection causing long lasting damage to my fingers.Soon after I started to pull out the tiny hairs on my legs during school assembles and by 12 I began to pull my eyebrow hair out.How can I stop doing this to myself? I don’t even realise I’m doing it half the time (I started biting the skin around my fingers just writing this and caused it to bleed a little). I’m afraid to bring this up with my parents because of how they have reacted in the past and I’m far too embarrassed to ask anyone I would typically trust. It has severally impacted how I interact with …